Ratings by Raymond James (Christopher Raymond)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/14/2026 | SpyGlass Pharma | SGP | New Coverage | Outperform (N/A) |
25.17 (27.31) |
8.5% | Details | |
| 6/15/2026 | Aktis Oncology | AKTS | New Coverage | Strong Buy (N/A) |
21.93 (23.94) |
9.17% | Details | |
| 5/11/2026 | Lexeo Therapeutics | LXEO | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/30/2026 | Alumis Inc | ALMS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/10/2026 | Climb Bio | CLYM | New Coverage | Strong Buy (N/A) |
7.25 (14.95) |
106.21% | Details | |
| 3/10/2026 | Alumis Inc | ALMS | New Coverage | Strong Buy (N/A) |
26.84 (9.90) |
-63.11% | Details | |
| 12/18/2025 | Lexeo Therapeutics | LXEO | New Coverage | Strong Buy (N/A) |
9.73 (4.36) |
-55.19% | Details |
